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Background: Pain is a common problem in people with dementia, however the exact prevalence of pain in dementia
subtypes, e.g. Alzheimer’s Disease (AD), Vascular Dementia (VaD), Frontotemporal Dementia (FTD) and dementia with
Lewy Bodies (DLB), is unknown, as is the relation between pain and the different subtypes of dementia. In this study, the
prevalence of pain in people with dementia will be investigated per dementia subtype and the relationship between
the various subtypes of dementia and the presence of specific types of pain (i.e. musculoskeletal pain, neuropathic pain
and orofacial pain) will be examined. Secondly, associations between various types of pain, cognitive functioning,
neuropsychiatric symptoms and quality of life in people with dementia will be examined. A third purpose is to study
the value of the assessment of autonomic responses in assessing pain in people with dementia. Finally, the effect of
feedback to the attending physician on the presence of pain, based on examination by investigators with backgrounds
in neuropsychology, geriatric dentistry and elderly care medicine, will be evaluated.
Methods/Design: A cross-sectional, partially longitudinal observational study in 400 participants with dementia, aged
60 years and older. Participants will be recruited from an outpatient memory clinic and dementia special care units. All
participants will be examined by an elderly care medicine trainee, a dentist with experience in geriatric dentistry, and a
neuropsychologist. The primary outcome is presence of pain. Secondary outcomes will include oral health, autonomic
responses to pain stimulus, vital sensibility and gnostic sensibility, musculoskeletal examination, cognitive functioning,
neuropsychiatric symptoms, and quality of life.
Discussion: This study will help to enhance our knowledge regarding the prevalence of different types of pain in
different dementia subtypes i.e. AD, VaD, FTD and DLB. This study also aims to contribute to a better understanding of
oral health status in people with dementia, the use of autonomic responses in the assessment of pain in people with
dementia and the relationships between pain and cognitive symptoms, neuropsychiatric symptoms and quality of life in
people with various dementia subtypes and in different stages of the disease.
Keywords: Aged, Alzheimer’s disease, Frontotemporal dementia, Vascular dementia, Dementia with Lewy Bodies, Pain,
Orofacial pain, Autonomic responses, Neuropsychiatric symptoms, Quality of lifeBackground
Pain is a common problem in people with dementia.
The prevalence of pain in people with dementia is high
[1-4]; there is good agreement in both large and small
studies that about 50% of the people with dementia
regularly experience pain [5]. This is not surprising,* Correspondence: j.vankooten2@vumc.nl
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Pain in dementia is associated with occurrence of
neuropsychiatric symptoms [8,9], and also with a decline
in cognitive functioning, as well as in performance of
Activities of Daily Living (ADL) [10]. Next to neuro-
psychiatric symptoms, pain is the most cited reason for
a decrease in quality of life in dementia [11]. Therefore,
recognition and adequate treatment of pain in people
with dementia should have high priority.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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prevalence between dementia subtypes is scarce, it is
suggested that differences in neuropathology between
dementia subtypes could be of vital importance in the
treatment of pain [12]. Results from previous small
studies showed that specific neuropathological changes
may affect pain experience and pain perception differ-
ently in the four commonest dementia subtypes [12],
i.e., Alzheimer’s Disease (AD), Vascular Dementia (VaD),
Dementia with Lewy Bodies (DLB), and frontotemporal
dementia (FTD). It is suggested that with a preponderance
of white matter lesions, pain experience in VaD may in-
crease compared to other dementia subtypes [12], while in
AD and FTD it is hypothesized that neuropathological
changes like gray matter atrophy lead to an increase in
pain tolerance [13-15].
Current knowledge about the prevalence of specific
types of pain, e.g., musculoskeletal pain or neuropathic
pain, and causes of pain in people with dementia is lim-
ited. Nociceptive pain of musculoskeletal origin is con-
sidered the most prevalent pain type, but orofacial pain
and neuropathic pain are also likely to have considerable
prevalence rates [16,17]. For example, orofacial pain is
one of the most prevalent types of pain in older people,
and has hardly been studied in people with dementia
[17,18]. Assessment of the specific type of pain and
classifying its probable causes would be useful as a com-
plement for the assessment of pain in people with de-
mentia, and would provide a sound basis for appropriate
pain treatment when combined with dementia subtyping
in people with dementia.
An important problem encountered in the assessment
of pain in patients with dementia, especially in more
advanced stages, is that assessment often is based on ob-
servation and interpretation of behavior, for which the val-
idity is unequivocally established [5,19,20]. More objective
methods for assessing pain in a more indirect way in this
population are therefore warranted. Assessing autonomic
responses to pain might be such a method [16,21].
Considering the limited number of studies on pain in
each subtype of dementia, and the absence of studies on
type of pain in dementia subtypes and in different stages
of dementia, we developed a unique multidisciplinary
approach. Investigators with backgrounds in neuropsych-
ology, geriatric dentistry, elderly care medicine, and pain
medicine will study in close cooperation the presence and
type of pain, in various stages of the four main subtypes of
dementia (AD, VaD, FTD and DLB). In a subset of patients
we will explore the feasibility of measuring autonomic
responses as a tool to assess the presence of pain.
Research aims
The primary aim of this study is to investigate the preva-
lence and intensity of pain (subtypes) in the four maindementia subtypes and to examine the relationship
between the different types of pain and the different
dementia subtypes, i.e., AD, VaD, FTD and DLB.
Secondary aims are:
– to examine the associations between neuropsychiatric
symptoms and pain, quality of life and pain, and
cognitive function and pain for all different dementia
subtypes;
– to explore whether autonomic responses can be
used for assessing pain in patients with more
advanced stages of dementia;
– to test the psychometric properties of the newly
developed Orofacial Pain Scale for Non Verbal
Individuals (OPS-NVI).
– to examine the oral health of older adults with
dementia.
– evaluate the effect of providing feedback on the
presence of pain (including treatment advice), to the
attending physician and/or dentist.
Methods/Design
Study design
This protocol describes an observational, cross-sectional
and partly longitudinal cohort study. Measurements take
place at baseline, and for the people with pain at base-
line, a follow-up pain measurement takes place after
3 months.
Recruitment
To ensure this study population covers the broad range
of the elderly population with dementia, participants
will be recruited in different stages of dementia. Partici-
pants with mild to moderate dementia, will be recruited
at the outpatient memory clinic of the Center of
Geriatric Medicine Amsterdam (COGA), VU University
medical center. Participants with moderate to severe
dementia will be recruited from Amstelring, a health
organization delivering specialized care to residents with
dementia in 17 nursing homes covering a large area in
the northwestern part of the Netherlands, including
Amsterdam.
Inclusion criteria
Participants who meet the following criteria will be in-
cluded: aged 60 or older, diagnosis of dementia, i.e. AD,
VaD, FTD, or DLB, and a signed informed consent by
the participant or legal representative.
Exclusion criteria
Primarily mentally disabled persons who subsequently
develop dementia, e.g. people with Down’s syndrome
and AD, will be excluded. Persons who indicate either
verbally or non-verbally, that they do not wish to
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consent by a legal representative.
Ethical approval and informed consent
The study protocol has been approved by an accredited
Medical Ethics Review Committee (VU University Medical
Center; NL.43861.029.13).
Informed consent will be obtained of all participants.
For participants unable to give consent, the legal repre-
sentative will be asked to sign an informed consent
form.
Measurement instruments
Variables measured in this study (primary outcome
measures, secondary outcome measures, demographic,
and control variables) are summarized in Table 1. These
will be assessed by using a combination of self-reportTable 1 Measurement instruments
Instrument Source
Rey Auditory Verbal Learning Test (15 Word Test) 1
Amsterdam Dementia Screening Test -Meander (ADS-6) 1
Behavioural Assessment of the Dysexecutive Syndrome
(BADS) – Rule Shift Cards
1
Brief Pain Inventory (BPI) 1
Dementia Quality of Life (DQoL) 1,2
Faces Pain Scale – Revised (FPS-R) 1
Global Deterioration Scale (GDS) 3
Katz-ADL
Mini Mental State Exam (MMSE) 1
Mobilization Observation Behaviour Intensity Dementia-2
(MOBID-2) Pain Scale
3
Neuropsychiatric Inventory- Nursing Home (NPI-NH) 3
Neuropsychiatric Inventory- Questionnaire (NPI-Q) 2
Numeric Rating Scale (NRS) 1
Orofacial Pain Scale for Non Verbal Individuals (OPS-NVI) 3
Oral Examination 1
Pain Assessment IN Advanced Dementia (PAINAD) 3
Quantitative Sensory Testing (QST) 1
Qualidem 3
Revised Index for Social Engagement (RISE) 3
Rey Complex Figure Test (RCFT) 1
Stroop Color-Word Test 1
Structured physical examination 1,3
Trail Making Test (TMT) 1
Verbal Descriptor Scale (VDS) 1
Verbal Fluency Test (VFT) - Animals 1
Visual Association Test (VAT) 1
VU University- Ambulatory Monitoring System (VU-AMS) 1
1 = Patient, 2 = Caretaker, 3 = Health professionals, T0 = baseline, T1 = after 3 moninstruments and observational instruments, which are
completed by caretaker or by a contact nurse.
Primary outcomes
The primary outcome will be: the presence and intensity
of pain in dementia subtypes. Pain will be assessed, using
a combination of methods concurrently.
In participants who are able to communicate about
the presence of pain, the Brief Pain Inventory (BPI) will
be applied [22]. The BPI is a questionnaire, assessing the
severity of pain by four numeric rating scale items and,
explores the degree to which pain interferes with daily
activities by seven interference items. The BPI is a valid
and reliable assessment tool for pain assessment in epi-
demiological studies [22]. Concurrently with the BPI, the
participant will be asked to score the intensity of pain,
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(VDS) [23-25], and Faces Pain Scale Revised (FPS-R)
[26,27] can be used for this purpose, dependent on
understanding by the participant of each of the scales.
In participants with difficulties to communicate their
pain, a contact nurse will be asked to complete the Pain
Assessment IN Advanced Dementia Scale (PAINAD)
[28]. The PAINAD is a brief and easy to administer
observational scale, especially used in people with
advanced dementia. The reliability and validity of the
PAINAD have been studied extensively and a cut-off
score of 2 has been recommended to indicate the
probable presence of pain [28-32].
Apart from these pain assessment tools, the Mobilization
Observation Behaviour Intensity Dementia-2 (MOBID-2)
Pain Scale [33] will be administered in all participants
by a contact nurse to measure pain, using standardized
movements. The MOBID-2 is a reliable, valid and time
effective instrument to measure pain in people with
advanced dementia [33]. For this study, the MOBID-2
was translated into Dutch, based on the guidelines for
cross-cultural adaptation [34]. The translated version
showed good feasibility in a pilot study. An overall
score of NRS ≥ 3 in the MOBID-2 will be regarded as
clinically relevant pain [33].
For the measurement of orofacial pain, Delwel and
Lobbezoo developed the Orofacial Pain Scale for Non
Verbal Individuals (OPS-NVI), based on [17] and [35],
which demonstrated good face validity and usability in a
pilot study. For further validation of the OPS-NVI, a
number of steps will be performed. First, the verbal and
nonverbal participants will be observed using the OPS-
NVI, during rest, drinking, eating, and mouth care.
These activities will be observed for indicators of pain
behavior and the pain intensity will be assessed by two
observers, whenever possible. Second, the group of ver-
bal participants will be asked about the presence of pain
and, if pain is present, the pain intensity with the NRS,
VDS, and FPS-R. Third, a standardized dental examin-
ation will be performed in both verbal and nonverbal
participants, to evaluate their oral health, which will be
described hereafter. The results of observation, self-
assessment and the dental examination will be compared
in order to validate the OPS-NVI.
Secondary outcomes
Secondary outcomes include oral health, autonomic
responses to a pain stimulus, vital sensibility, musculo-
skeletal examination, cognitive functioning, neuropsychi-
atric symptoms, and quality of life.
Oral health
Oral health will be evaluated by a dentist with experi-
ence in geriatric dentistry, performing a structured oralexamination, including history taking, extraoral, functional,
intraoral, and (whenever indicated) additional examination.
The function of the temporomandibular joint will
be assessed with an Active Mandibular Examination
(AME). The participant will be asked to make different
jaw movements and the dentist will measure the excur-
sions [36]. The presence or absence of pain will be
observed; if the procedure is too painful, it will be
stopped [37]. Whenever applicable, removable pros-
thetics will be examined for hygiene, retention, and
occlusion/articulation [38]. The status of the oral tissues
will be determined by examining the lips, cheeks, palate,
tongue, floor of the mouth, alveolar ridges, saliva, and
mouth odor. These elements will be classified as healthy
or abnormal by the dentist [38]. The number of opposing
molars, the occlusal units (OU), will be counted as an in-
dication of the chewing ability [39]. The status of the par-
ticipant’s natural teeth will be scored with the Decayed
Missing and Filled Teeth (DMFT) Index [40]. For this
index, the number of teeth with caries, missing teeth, and
teeth with fillings will be recorded. Also the amount of
dental wear will be quantified and itemized [41]. The
periodontal status will be determined by measuring the
periodontal pockets according to the Dutch Periodontal
Screening Index (DPSI) [42] and the physiological mobil-
ity of the teeth [43]. The oral hygiene will be measured,
according to the Plaque Index by Silness and Loe [44].
Somatosensory changes of the face will be examined with
brief quantitative sensory tests for orofacial pain. Three
simple tests will be used: a cotton swab, pinprick, and
brush test. The three innervation areas of the N. Trigem-
inus will be tested: above the eyebrow, under the eye and
at the lower lip. The results will be used to determine if a
participant has signs of neuropathic pain in the orofacial
region [45]. For determining of signs of neuropathic pain
elsewhere in the body, testing of vital and Quantitative
Sensory Testing (QST) will be done (see below).
The oral examination will be evaluated and given as
feedback to the participant, caretakers and/or medical
staff.
Autonomic responses to pain stimulus
Autonomic responses to pain will be measured with
the VU University Ambulatory Monitoring System
(VU-AMS), a certified device that records the elec-
trocardiogram (ECG) and changes in thorax imped-
ance (dZ) to determine Inter-Beat-Interval (IBI), Pre
Ejection Period (PEP), and Respiratory Sinus Arrhythmia
(RSA). In addition, Skin Conductance Level (SCL) will be
recorded using the VU-AMS by two electrodes (Biopac
TSD203) combined with their isotonic electrode gel
(GEL101) on the index and middle finger [46-48].
At the outpatient memory clinic autonomic responses
to a pain stimulus in the form of a venipuncture will be
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to rate their current pain on the NRS followed by a
two minute rest and a baseline measurement. Next, a
venipuncture will be performed by a geriatric nurse
and directly after this procedure the patient will be
asked to rate the pain intensity of the venipuncture on
the NRS. Subsequently, a second baseline measurement
will be performed during a three-minute rest period. The
patients will be asked to rate their current pain after the
second baseline measurement to ensure that their pain
level is not increased by sitting still for a prolonged
period of time.
In nursing home residents, autonomic responses to
pain stimuli are only measured in patients who undergo
changes of wound dressings as part of usual care in the
treatment of pressure ulcers. First the patients who are
able to communicate, will be asked to rate their current
pain level on the NRS followed by a five minute baseline
measurement in rest. After the baseline measurement,
the wound treatment procedure will be explained. The
renewal of the wound dressing will be utilized as a
painful episode. The current wound dressing will be
removed, the wound cleaned and new dressing will be
applied. Afterwards, the pain intensity of the treatment
episode will be assessed in verbal patients by using the
NRS. Finally, another 5 minute baseline measurement in
rest will be performed.
Vital sensibility
Vital sensibility will be assessed by Quantitative Sensory
Testing (QST), including touch perception, sharp/dull
distinction and temperature discrimination. All sensory
procedures will be administered to the inside of both
lower arms. This site is often used in somatosensory
studies [49,50] because of the high density of intra-
epidermal nerve fibers [51]. QST will only be performed
in patients with a Mini Mental State Examination
(MMSE)-score ≥ 14.
The touch perception threshold will be assessed by
nylon monofilaments based on the Von Frey hairs
(Somedic AB, Sweden). A maximum number of 19
filaments will be administered to the inside of both
lower arms, until the participant indicates the sensation
of touch. False positive responses will be controlled by
administering a null stimulus (no filament administered).
The monofilaments increase in diameter, resulting in an
increase in force that is applied to the skin. The monofil-
aments are numbered in ascending order. The number
of the first monofilament resulting in a response will be
used as an outcome.
The ability to sense the difference between sharp and
dull stimuli will be assessed using the Neuropen (Owen
Mumford, U.S.A.). This instrument contains both a
monofilament for touch and a tip for sharpness. Themonofilament will be pressed to the skin surface at a 90°
angle until it bows (10 g) and subsequently hold in this
position for 2 seconds. The sharp tip will be pressed to
the skin surface at a 90° angle, until the marker is within
the 40 g marker zone and subsequently held in this pos-
ition for 2 seconds. Number of errors (maximum of 6)
will be used as the outcome measure.
For temperature discrimination the Rolltemp (Somedic
AB, Sweden) will be applied in random order to the left
forearm (total of 3 times) and to the right forearm (total
of 3 times). The subject will have to indicate whether
the stimulus was cold or warm. The rollers will be
placed in their docking stations between trials so their
temperature is either 25 °C or 40 °C. Compared with the
normal human skin temperature of 32 °C, the rollers will
be perceived as either cold or warm, by humans with
normal temperature sensitivity. The number of errors
(maximum six) will be used as an outcome measure.
Musculoskeletal examination
A structured musculoskeletal examination will be per-
formed by a physician in patients with clinically pain to
determine whether the pain originates from the muscu-
loskeletal system. Clinically relevant pain is either defined
as BPI score ≥ 3, or self-report score ≥ 3, or MOBID-2 pain
score ≥ 3, or PAINAD score ≥2.
Cognitive functioning
Cognitive functioning will be measured using the follow-
ing memory measures: (1) the 15 Word test [52,53]
adapted from the Rey Auditory Verbal Learning Test
[54], (2) the Meander from the Amsterdam Dementia
Screening Test [55], (3) the Rule Shift Cards Tests sub-
test of the Behavioural Assessment of the Dysexecutive
Syndrome [56], (4) the Rey Complex Figure Test [57],
(5) the Stroop Color-Word Test [58], (6) the Trail
Making Test [59], (7) the Verbal Fluency Test Animals
[60], (8) the Visual Association Test [61], and (9) the
Mini Mental State Examination (MMSE) [62], a brief
instrument used to screen for cognitive impairment and
well validated in both research and clinical practice
[63,64]. In nursing home patients only the MMSE will
be used for measuring cognitive functioning.
Neuropsychiatric symptoms
Neuropsychiatric symptoms will be measured with a brief
questionnaire form of the Neuropsychiatric Inventory
(NPI-Q) [65] in participants at the outpatient memory
clinic, and with the Neuropsychiatric Inventory Nursing
Home Version (NPI-NH) [66] in nursing home residents.
The NPI-Q is a revised version of the original NPI and
has been validated against the original NPI [67]. The
NPI-NH is developed for rating by professional care-
givers within institutions and proved to be valid and
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the only nursing home instrument for a broad range of
neuropsychiatric symptoms that has been translated into
Dutch [69].
Quality of life
Quality of life will be assessed by the Dementia Quality
of Life instrument (DQol) [70] or the Qualidem [71,72].
The DQol is a valid instrument to assess the quality of
life in persons with a mild to moderate stage of demen-
tia. In people with moderate to severe dementia, the
Qualidem will be used, which is a reliable and valid in-
strument that provides a quality of life profile of persons
living in nursing homes [71,72].
In addition to quality of life, social participation will be
measured using the Revised Index for Social Engagement
(RISE) [73]. The RISE is a valid instrument for assessing
social engagement in nursing home residents and contains
six questions about the social interaction of the participant.
A contact nurse who is familiar with the participant
completes this questionnaire [73].
Dementia subtype and Stage
Participants recruited at the outpatient memory clinic
will be screened for dementia, including Computed
Tomography (CT) or Magnetic Resonance Imaging
(MRI). The clinical diagnosis will be established by
consensus within a multidisciplinary consultation. The
National Institute of Neurological and Communicative
Disorders and Stroke (NINCDS) and the Alzheimer’s
Disease and Related Disorders Association (ADRDA)
criteria for Alzheimer dementia [74], the National Institute
of Neurological Disorders and Stroke Association (NINDS)
Internationale pour la Recherche et l’Enseignement en
Neurosciences (AIREN) criteria for vascular dementia [75],
the revised criteria for FTD [76], and the revised criteria
for DLB [77] are used. Participants recruited from demen-
tia special care units will have a diagnosis of dementia
usually based on DSM-IV criteria (2000), and the medical
record will be reviewed for a probable subtype diagnosis
determined by a geriatrician, neurologist, elderly care phys-
ician, or old age psychiatrist, and preferably completed by
CT or MRI.
Dementia stage will be determined using the Global
Deterioration Scale (GDS), a well-validated seven point
scale [78]. The GDS defines seven stages of dementia,
ranging from ‘no global impairment’ (1) to ‘very severe
global impairment’ (7) [78].
Demographics, baseline, and control variables
Patient characteristics (i.e. sex and age) will be derived
from medical records. The Charlson co-morbidity Index
[79] will be used to classify co-morbidities, while ADL
performance will be measured by the Katz-ADL [80]. TheKatz-ADL assesses functional status and is used extensively
in the field of elderly care medicine and geriatrics.
Medication
Information on medication use will be derived from the
medical records at the outpatient memory clinic. To
ensure a complete overview of pain medication, partici-
pants will explicitly be asked about their use of over-
the-counter pain medication. In the nursing homes
information on medication use will be derived from
the pharmacists’ electronic patient records.
Study procedure
Study measures after consent at the outpatient
memory clinic
Measurements will be performed during the memory-
screening day in the outpatient clinic. Since several mea-
surements are already part of the standard routine, for re-
search purposes the following measurements will be added,
i.e. a structured pain assessment, an oral examination, the
measurements of autonomic responses and sensibility
(touch perception, sharp/dull distinction, temperature dis-
crimination), the presence of neuropsychiatric symptoms,
and the measurement of quality of life. Demographics,
dementia subtype diagnosis, cognitive performance (i.e.
neuropsychological assessment), ADL (i.e. Katz-ADL), co-
morbidity (i.e. Charlson co-morbidity Index), and pre-
scribed medication will be obtained from medical notes.
At the start of the memory-screening day, the neuro-
psychologist will install the VU-AMS device after which
the VU-AMS protocol will be executed.
Participants will undergo a physical examination by a
physician from the outpatient clinic; for this study, the
physical examination will comprise a structured examin-
ation of the musculoskeletal system. Besides, patients
will undergo QST by a trained neuropsychologist or re-
search assistant. A dental examination will be performed
by a dentist with experience in geriatric dentistry.
If pain is observed in participants, recruited in the out-
patient memory clinic, feedback about the pain and the
most probable cause(s) will be given to the attending
physician.
Study measures after consent in nursing homes
To reduce participant burden, measurements in nursing
home residents will be split into three parts, which
will preferably be performed on 3 different days; i.e.
(1) structured pain assessment including musculo-
skeletal examination when clinically relevant pain is
present, (2) oral examination, and (3) cognitive as-
sessment, QST and VU-AMS, if applicable. Structured
pain assessment includes the BPI, self-report-scales,
or PAINAD. Besides, all participants will be observed
for presence of pain during morning care using the
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neuropsychiatric symptoms, quality of life, participation,
and ADL by interviewing the contact nurse. Dental exam-
ination will be performed by a dentist. Cognitive assess-
ment will be done by a neuropsychologist. QST will only
be assessed in patients with a MMSE-score ≥ 14, and the
VU-AMS will only be used in nursing home residents who
undergo changes of wound dressings as part of usual
decubitus care.
If pain is observed in nursing home residents during
baseline measurement, feedback about the type(s) of
pain and a differential diagnosis of the most probable
cause(s), including information about treatment options,
will be given to the attending physician. Reassessment of
these participants will take place after three months with
the same pain measurement instruments as applied at
baseline. During this reassessment, information about
pain treatments in the last three months will be col-
lected to evaluate the effect of feedback to the attending
physician.
Sample size and power analysis
Our first objective is to assess the prevalence of pain in
dementia subtypes. To date, no clear estimates of the
prevalence of pain in dementia subtypes are known.
Therefore, we used an assumed prevalence of 50% for
our sample size calculation. Aiming at a precision of
5 percentage points (i.e., estimate +/− 2.5%) with a sig-
nificance level (alpha) of 0.05 and a power (beta) of 0.95,
we will need to recruit 384 participants. Taking into con-
sideration that prevalence measurements do not require
follow-up, we did not correct for attrition.
To analyze the assumed association between neuro-
psychiatric symptoms and pain, quality of life and pain,
and cognitive functioning and pain in all different de-
mentia subtypes, multivariable linear regression analyses
will be used. Power depends on the amount of explanatory
variables and therefore we decided to include a maximum
of 10 explanatory variables in our analyses. Based on the
sample size calculations, using the software-tool ‘G*power
version 3.1.2’ [81], 118 participants per major dementia
subtype (i.e. AD and VaD) need to be recruited to ensure a
95% confidence interval with 80% power.
Data analysis
We will use descriptive statistics for the demographic
features of the cohort. The prevalence and intensity of
pain and the causes of pain will be determined in the
overall group of people with dementia. In addition, the
frequency of pain subtypes per dementia subtype and
dementia stage will be analyzed for group differences
using Chi square tests.
For the secondary outcome analyses, descriptive statis-
tics and multivariable linear regression analyses will beused. Multivariable linear regression will be used to
evaluate the relationships between neuropsychiatric
symptoms and pain, quality of life and pain, and cogni-
tive functioning and pain, in dementia subtypes.
Differences in autonomic responses per dementia sub-
type, measured by the VU-AMS, as well as the effect of
feedback on the presence of pain will be analyzed using
paired t-tests.
Discussion
The aim of the study is to investigate the prevalence and
intensity of pain in the major dementia subtypes and for
different dementia stages, as well as the relationship be-
tween the different types of pain and the major dementia
subtypes. Primary outcome is the presence and intensity of
pain in dementia subtypes. Secondary outcomes are oral
health, autonomic responses to pain stimuli, vital sensitiv-
ity, cognitive functioning, neuropsychiatric symptoms, and
quality of life. Additionally, an evaluation of effectiveness
of feedback on the presence of pain will be carried out, and
the possibility of using autonomic responses for assessing
pain in patients with dementia will be explored.
In this study, a unique multidisciplinary approach is
used, in which a neuropsychologist, dentist, and elderly
care medicine trainee all examine the same group of
participants. All participants will have a cognitive assess-
ment, an oral examination and physical assessment.
Results will be gathered and a differential diagnosis,
including a treatment advice, if desired, will be provided
to the attending physician.
We assume that the prevalence of pain will be differ-
ent for the four most common dementia subtypes, and
will be the highest in VaD and we expect to see more
neuropathic pain in VaD, in which it is more likely to
see neuropathic pain due to white matter lesions [12,82].
This study will provide data about the prevalence and
intensity of orofacial pain and oral health problems in
persons with dementia. Although there is an increase in
attention for oral health in people with dementia, studies
on oral health in people with dementia are scarce.
Furthermore, available data indicate that oral health in
people with dementia is poorer compared to cognitive
intact people [83].
The chosen design seems suitable for our purposes.
We will include patients in all different stages of the dis-
ease by recruiting at the outpatient memory clinic and
in nursing homes, and we will also consider all possible
causes of pain that are most likely to be diagnosed due
to our multidisciplinary approach. The chosen measure-
ment instruments are all commonly used in the field of
elderly care medicine and geriatrics, except for the
MOBID-2,OPS-NVI and the VU-AMS.
Observational pain assessment tools have limited
validity and could lead to misinterpretation of pain
van Kooten et al. BMC Geriatrics  (2015) 15:29 Page 8 of 10behavior. For example, a grimace might be interpreted as
a smile, or a positive score on an observational pain tool
might be attributed to pain instead of some other cause of
distress [20]. However, there is currently no better method
of assessing pain in a population with severe dementia
beyond the proposed approach in this study. We acknow-
ledge that this may lead to an overdetection of pain in this
study. As we use several observational instruments this
enables to determine correlations between the instru-
ments. This will give insight in the probability of overde-
tection and also enhance knowledge about the concurrent
validity of the instruments.
For that reason we planned to investigate the contri-
bution of autonomic responses to pain stimuli and QST
as more objective measurement methods in the assess-
ment of pain in people with dementia. The reliability of
QST in people with dementia has already been demon-
strated [21], although the use of QST in epidemiologic
studies on pain in dementia is scarce.
The success of this study in nursing home residents
depends highly upon support of the nursing staff. Par-
ticipating in this research may be perceived as time-
consuming by the nursing staff. Therefore, we decided
to support the nurses by deploying research assistants.
The research assistants will collect data on behavior,
quality of life, participation, and ADL by interviewing
the contact nurse to ensure that participation is as little
time-consuming as possible. These research assistants
will be trained in administering the instruments correctly
and consistently.
In conclusion, this study will help to enhance our
knowledge regarding the prevalence of different types of
pain in different dementia subtypes i.e. AD, VaD, FTD
and DLB. This study also aims to contribute to a better
understanding of oral health problems in people with
dementia and the relationships between pain and cogni-
tive symptoms, neuropsychiatric symptoms, and quality
of life in people with various dementia subtypes and in
different stages of the disease.
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